Landmark Bio
Watertown, MA
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Landmark Bio
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Watertown, MA
- Modalities
- AAV, Lentiviral, CAR-T, Cell Therapy, mRNA, LNP, Extracellular Vesicles, Gene Editing
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Landmark Bio
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, CAR-T, Cell Therapy, mRNA, LNP, Extracellular Vesicles, Gene Editing
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (8 modalities)
Recent News 10 articles
New genetic medicine CDMO acquires Landmark Bio - BioPharma Dive
Gene therapy CDMO Artis BioSolutions launches with acquisition of Landmark Bio - Fierce Pharma
New CDMO emerges, acquires cell and gene manufacturer Landmark Bio - Endpoints News
Artis BioSolutions Emerges from Stealth, Announces Acquisition of Landmark Bio - Business Wire
Landmark Bio, a biomanufacturing facility co-founded by MIT, breaks ground in Watertown Arsenal - MIT News
Landmark Bio tackles cell therapy manufacturing hurdles - drugdiscoverytrends.com
An unusual alliance opens a gene and cell therapy hub outside Boston - BioPharma Dive
Artis BioSolutions Emerges from Stealth, Acquires Landmark Bio - Contract Pharma
CDMO AmplifyBio closes doors amid tough market for early-stage cell and gene therapy development - Fierce Pharma
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care - PR Newswire
Frequently Asked Questions About Landmark Bio
What is Landmark Bio's CDMO Signal Score?
Landmark Bio has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Landmark Bio for a manufacturing program?
Use the free AI matchmaker to compare Landmark Bio against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Rose BioSolutions
Wilmington, MA
Plasmid DNA, AAV, Lentiviral, Adenoviral, CAR-T, Cell Therapy, Gene Editing, Cell Solutions / Starting Materials
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy
Lonza
Basel, Switzerland
Signal Score: 78.2
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein